Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Other financing activities (2021 - 2022)

Prime Medicine's Other financing activities history spans 2 years, with the latest figure at $1.4 million for Q4 2022.

  • For Q4 2022, Other financing activities rose 28.91% year-over-year to $1.4 million; the TTM value through Sep 2023 reached $1.4 million, down 62.45%, while the annual FY2022 figure was $4.0 million, 272.19% up from the prior year.
  • Other financing activities reached $1.4 million in Q4 2022 per PRME's latest filing, up from $746000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $1.4 million in Q4 2022 to a low of $624000.0 in Q2 2022.